Literature DB >> 12375012

Restoration of estrogen responsiveness by blocking the HER-2/neu pathway.

Lois Witters1, Linda Engle, Allan Lipton.   

Abstract

HER-2/neu gene amplification or protein overexpression is evident in 20-30% of primary breast cancers. Its amplification correlates with poor prognosis. There appears to be an association between HER-2/neu overexpression and estrogen independence. The MCF-7 human breast carcinoma cell line is estrogen-dependent and sensitive to the anti-estrogen, tamoxifen (TAM). This line, when transfected with the HER-2/neu gene, becomes estrogen-independent and resistant to TAM. Blockade of the HER-2/neu receptor with 1-5 nM of the humanized HER-2/neu antibody, Herceptin, restored estrogen, as well as TAM, sensitivity. These results suggest that Herceptin or similar drugs may restore estrogen sensitivity and the administration of a HER-2/neu inhibitor with an anti-estrogen to premenopausal patients should be considered.

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12375012

Source DB:  PubMed          Journal:  Oncol Rep        ISSN： 1021-335X            Impact factor:   3.906


  11 in total

Review 1.  Growth factor signalling in endocrine and anti-growth factor resistant breast cancer.

Authors:  R I Nicholson; I R Hutcheson; H E Jones; S E Hiscox; M Giles; K M Taylor; J M W Gee
Journal:  Rev Endocr Metab Disord       Date:  2007-09       Impact factor: 6.514

2.  Tamoxifen resistance and Her2/neu expression in an aged, irradiated rat breast carcinoma model.

Authors:  Norman C Peterson; Matthew D Servinsky; Archie Christian; Zhongsheng Peng; Weiping Qiu; Jill Mann; John Dicello; David L Huso
Journal:  Carcinogenesis       Date:  2005-04-28       Impact factor: 4.944

3.  Randomized phase III placebo-controlled trial of letrozole plus oral temsirolimus as first-line endocrine therapy in postmenopausal women with locally advanced or metastatic breast cancer.

Authors:  Antonio C Wolff; Ann A Lazar; Igor Bondarenko; August M Garin; Stephen Brincat; Louis Chow; Yan Sun; Zora Neskovic-Konstantinovic; Rodrigo C Guimaraes; Pierre Fumoleau; Arlene Chan; Soulef Hachemi; Andrew Strahs; Maria Cincotta; Anna Berkenblit; Mizue Krygowski; Lih Lisa Kang; Laurence Moore; Daniel F Hayes
Journal:  J Clin Oncol       Date:  2012-12-10       Impact factor: 44.544

Review 4.  Current approaches and future directions in the treatment of HER2-positive breast cancer.

Authors:  Sara A Hurvitz; Yufang Hu; Neil O'Brien; Richard S Finn
Journal:  Cancer Treat Rev       Date:  2012-05-31       Impact factor: 12.111

Review 5.  HER story: the next chapter in HER-2-directed therapy for advanced breast cancer.

Authors:  Sunil Verma; Anil A Joy; Daniel Rayson; Deanna McLeod; Christine Brezden-Masley; Jean-François Boileau; Karen A Gelmon
Journal:  Oncologist       Date:  2013-11-08

Review 6.  Clinical utility of the combination of lapatinib and letrozole in the management of hormone receptor-positive and HER2-positive advanced breast cancer.

Authors:  Priscilla Merriam; William M Sikov
Journal:  Breast Cancer (Dove Med Press)       Date:  2011-10-26

Review 7.  Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family: molecular mechanism and clinical implications for endocrine therapy resistance.

Authors:  Grazia Arpino; Lisa Wiechmann; C Kent Osborne; Rachel Schiff
Journal:  Endocr Rev       Date:  2008-01-23       Impact factor: 19.871

8.  Status of HER-2/neu receptors and Ki-67 in breast cancer of Indian women.

Authors:  Rajeev Singhai; Vw Patil; Av Patil
Journal:  Int J Appl Basic Med Res       Date:  2011-01

Review 9.  Femara and the future: tailoring treatment and combination therapies with Femara.

Authors:  Matthew Ellis; Cynthia Ma
Journal:  Breast Cancer Res Treat       Date:  2007-10-03       Impact factor: 4.872

Review 10.  The patient experience.

Authors:  Nadia Harbeck; Renate Haidinger
Journal:  Breast Cancer Res Treat       Date:  2007-10-03       Impact factor: 4.872
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.